Metastatic pheochromocytoma and paraganglioma: Somatostatin receptor 2 expression, genetics and therapeutic responses.
Alessa FischerSimon KloosUmberto MaccioJuliane FriemelHanna RemdeMartin FassnachtChristina PamporakiGraeme EisenhoferHenri J L M TimmersMercedes RobledoStephanie M J FliednerKatharina WangJulian MaurerAstrid ReulKathrin ZitzmannNicole BechmannGintarė ŽygienėSusan RichterConstanze HantelDiana VetterKuno LehmannHermine MohrNatalia S PellegataMartin UllrichJens PietzschChristian G ZieglerStefan R BornsteinMatthias KroissMartin ReinckeKarel PacakAshley B GrossmanFelix BeuschleinSvenja NöltingPublished in: The Journal of clinical endocrinology and metabolism (2023)
SSTR2 expression was independently associated with SDHB/SDHx mutations and metastatic disease. We confirm a high disease control rate of somatostatin receptor-based therapies in metastatic PPGLs.